BioLife Solutions vs Envista
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put BioLife Solutions and Envista side by side, using each oneβs latest annual report. Here is what stands out:
- Envista is the larger business, with $2.7B of revenue in fiscal 2025 against $96.2M for BioLife Solutions, about 28 times as much.
- BioLife Solutions grew revenue faster (28.9%, against 8.3%).
- Envista kept more of each dollar of sales as operating profit (8.0% operating margin, against β17.3%).
- BioLife Solutions turned more of its sales into free cash flow (11.1% FCF margin, against 8.5%).
- Envista earned a higher return on the capital invested in it (3.2%, against β4.8%).
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
BioLife Solutions
BLFS
4/10
Revenue growth5-year growthGross marginFCF margin
Envista
NVST
6/10
Operating marginNet marginReturn on capitalReturn on equityPiotroski F-scoreShare count change
Side by side
Best in the row
| Latest fiscal year | BLFS FY25 | NVST FY25 |
|---|---|---|
| Size | ||
| Market cap | β | $3.9B |
| Revenue | $96.2M | $2.7B |
| Free cash flow | $10.6M | $230M |
| Net income | β$4.6M | $47.0M |
| Growth | ||
| Revenue growth | 28.9% | 8.3% |
| 5-year growth | 14.9% | 7.1% |
| Share count change | 5.6% | β1.7% |
| Profitability | ||
| Gross margin | 64.6% | 54.7% |
| Operating margin | β17.3% | 8.0% |
| Net margin | β4.8% | 1.7% |
| FCF margin | 11.1% | 8.5% |
| Return on capital | β4.8% | 3.2% |
| Return on equity | β1.3% | 1.6% |
| Balance sheet | ||
| Net debt | β$83.9M | $237M |
| Net debt / EBITDA | β | 0.7x |
| Dividends and buybacks | $0.0M | $167M |
| Valuation & quality | ||
| P/E | β | 40.8x |
| Piotroski F-score | 6 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.